Excluding revenue generated from RTPCR, Dr Lal PathLabs experienced a significant increase of 14.4 per cent in Q2 FY 2023-24
Read More
Sun Pharma reported a profit after tax of Rs 2,375 crore in the September quarter up by 5 per cent against Rs 2,262 crore in the corresponding quarter last year
Read More
The agreement involves an initial payment of GBP 68 million along with additional annual earn-outs until 2026, contingent upon achieving predetermined milestones related to the acquisition of the LiqMeds Group of companies. Zydus foresees this transaction as having a positive impact on its earnings per share (EPS)
Read More
Star Health's gross written premium grew by 17 per cent to Rs. 3,732 crore versus Rs. 3,193 crore in Q2 of the previous fiscal
Read More
Mankind Pharma's domestic revenue grew by 7 per cent YoY to Rs 2,529 crores while exports rose by 159 per cent YoY to Rs 179 crores
Read More
During the quarter, sales of Paxlovid saw a steep decline of 97 per cent, amounting to USD 202 million, while vaccine revenue amounted to USD1.31 billion, a considerable drop from the USD 4.4 billion recorded in the previous year
Read More
Most of the funding this year so far in this sector has come through late-stage investments, which stood at USD 340 million. Further, a total of 17 acquisitions have been observed in 2023 so far, compared with 17 in the same period in 2022
Read More
The company is raising around Rs 1000 crore from three leading banks including JP Morgan, CITI and SMBC for financing Rs 1600 crore acquisition and the remaining Rs 600 crore from internal accruals
Read More
